CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution
01 juin 2021 06h30 HE
|
CENTOGENE GmbH
World leader and trusted partner in rare diseases releases enhanced Whole Exome Sequencing (WES) solution to improve diagnosis in complex and unsolved patient casesNEW CentoXome® provides...
CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer
26 mai 2021 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 26, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals
18 mai 2021 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENE Extends Global Parkinson’s Disease Study
10 mai 2021 06h30 HE
|
CENTOGENE GmbH
Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD) The Rostock International Parkinson's Disease (ROPAD) Study aims to...
New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases
06 mai 2021 06h30 HE
|
CENTOGENE GmbH
Database has grown to more than 465,000 analyzed patients, with more than 225,000 being linked to HPO termsRelease includes increase of almost 19 million to over 31 million unique variants New...
CENTOGENE Discovers Six New Rare Diseases by Leveraging the Strength of Its Bio/Databank
05 mai 2021 06h30 HE
|
CENTOGENE GmbH
More than half of patients with genetic diseases remain undiagnosed, even after performing Exome and Genome SequencingBy performing deep genetic analyses and Bio/Databank mining, CENTOGENE discovers...
CENTOGENE Reports Record Fourth Quarter and Full Year 2020 Financial Results
15 avr. 2021 06h30 HE
|
CENTOGENE GmbH
Revenues more than doubled in FY 2020 compared to FY 2019 to a record €128.4 million, with Q4 2020 revenues nearly quadrupling year-over-year to a record €70.3 millionAchieved highest annual adjusted...
CENTOGENE Announces Voting Results of Extraordinary General Meeting
18 déc. 2020 10h02 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases...
CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance
16 déc. 2020 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases...
CENTOGENE to Report Third-Quarter 2020 Financial Results on December 16, 2020
09 déc. 2020 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...